Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies

被引：0
|
作者：
Lou, Yidan [1 ,2 ]
Chen, Yijing [1 ,2 ]
Guo, Kaibo [2 ,3 ]
Li, Binbin [2 ,4 ]
Zheng, Song [1 ,2 ,3 ,4 ]
机构：
[1] Zhejiang Univ, Sch Med, Hangzhou 310006, Peoples R China
[2] Hangzhou First Peoples Hosp, Dept Oncol, Hangzhou 310006, Peoples R China
[3] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou 310006, Peoples R China
[4] Zhejiang Chinese Med Univ, Sch Clin Med 4, Dept Oncol, Hangzhou 310006, Peoples R China
来源：
BIOMARKERS IN MEDICINE | 2024年 / 18卷 / 15-16期
关键词：
biliary tract cancers; biomarkers; immune checkpoint inhibitor; microbiome; PD-L1; tumor microenvironment; TUMOR MICROENVIRONMENT; PD-1; EXPRESSION; GUT MICROBIOME; CHOLANGIOCARCINOMA; CHEMOTHERAPY; BLOCKADE; CELLS;
D O I：
10.1080/17520363.2024.2385297
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Biliary tract cancers (BTCs) have rising incidence and mortality rates. Chemotherapy's limited efficacy has led to exploring new treatments like immunotherapy. which offers modest benefits. Moreover, the identification of reliable predictive biomarkers for immune checkpoint therapy in BTCs remains elusive, hindering personalized treatment strategies. This review provides an overview of the current landscape of emerging biomarkers for immunotherapy response in BTCs. We discuss the incremental benefits of combination therapy and the evolving role of immunotherapy in managing advanced BTC. Additionally, we highlight the need for robust predictive biomarkers to optimize treatment outcomes and foster a more individualized approach to patient care. We aim to identify promising research avenues and strategies to enhance therapeutic efficacy and patient survival in BTCs.
引用
收藏
页码：703 / 715
页数：13
相关论文
共 50 条
  • [1] The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers
    Giorgione, Roberta
    Risaliti, Matteo
    Bartolini, Ilenia
    Rossi, Gemma
    Pillozzi, Serena
    Muiesan, Paolo
    Taddei, Antonio
    Antonuzzo, Lorenzo
    IMMUNOTHERAPY, 2022, 14 (07) : 567 - 576
  • [2] A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract
    Liao, Xuqiang
    Li, Gao
    Cai, Renzhong
    Chen, Ru
    MEDICAL SCIENCE MONITOR, 2022, 28
  • [3] Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
    Lo, Justin H. H.
    Agarwal, Rajiv
    Goff, Laura W. W.
    Heumann, Thatcher R. R.
    CANCERS, 2023, 15 (13)
  • [4] Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers
    Gao, Yue
    Wang, Xinyue
    Dong, Longlong
    Qu, Changfan
    Lu, Qianyi
    Wang, Peng
    Xin, Mengyu
    Zheng, Wen
    Liu, Chenyu
    Ning, Shangwei
    SCIENTIFIC DATA, 2023, 10 (01)
  • [5] Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
    Arora, Sanjeevani
    Velichinskii, Rodion
    Lesh, Randy W.
    Ali, Usman
    Kubiak, Michal
    Bansal, Pranshu
    Borghaei, Hossein
    Edelman, Martin J.
    Boumber, Yanis
    ADVANCES IN THERAPY, 2019, 36 (10) : 2638 - 2678
  • [6] Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future
    Blair, Alex B.
    Murphy, Adrian
    CURRENT PROBLEMS IN CANCER, 2018, 42 (01) : 49 - 58
  • [7] Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma)
    Jakubowski, Christopher D.
    Azad, Nilofer S.
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (01)
  • [8] Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
    Li, Meng
    Kaili, Denis
    Shi, Lei
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 14 (01) : 19 - 37
  • [9] Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors
    Ma, Shuang
    Chen, Fei
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 238
  • [10] Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities
    Goodman, Rachel S.
    Jung, Seungyeon
    Balko, Justin M.
    Johnson, Douglas B.
    IMMUNOLOGICAL REVIEWS, 2023, 318 (01) : 157 - 166
12345